Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 1/2021

Open Access 01-01-2021 | Lymphoma | Letter to the Editor

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

Authors: Annalen Bleckmann, Sascha Dierks, Hans-Ulrich Schildhaus, Niels Hellige, Ulrike Bacher, Lorenz Trümper, Gerald Wulf

Published in: Annals of Hematology | Issue 1/2021

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S (2012) Burkitt’s lymphoma. Lancet. 379(9822):1234–1244CrossRef
2.
Dunleavy K, Little RF, Wilson WH (2016) Update on Burkitt lymphoma. Hematol Oncol Clin North Am 30(6):1333–1343CrossRef
3.
Meadows SA, Vega F, Kashishian A et al (2012) PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 119(8):1897–1900CrossRef
4.
Graf SA, Gopal AK (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17(2):265–274CrossRef
5.
Davies A (2015) Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes. Expert Rev Hematol 8(5):581–593CrossRef
6.
Love C, Sun Z, Jima D et al (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44(12):1321–1325CrossRef
7.
Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, Thiel E (2005) Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia. 19(8):1391–1398CrossRef
8.
Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM (2014) Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 4(2)
9.
Wan G, Pehlke C, Pepermans R, Cannon JL, Lidke D, Rajput A (2015) The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells. Cell Death Discov 1:15044CrossRef
10.
Sheen MR, Marotti JD, Allegrezza MJ, Rutkowski M, Conejo-Garcia JR, Fiering S (2016) Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 5(10):e267CrossRef
11.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R (2012) PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 3(12):1566–1575CrossRef
12.
Curnock AP, Knox KA (1998) LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells. Cell Immunol 187(2):77–87CrossRef
13.
Spender LC, Inman GJ (2014) Developments in Burkitt’s lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res 6:27–38PubMedPubMedCentral
14.
Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R (2013) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73(1):276–284CrossRef
Metadata
Title
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
Authors
Annalen Bleckmann
Sascha Dierks
Hans-Ulrich Schildhaus
Niels Hellige
Ulrike Bacher
Lorenz Trümper
Gerald Wulf
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 1/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-03974-y

Other articles of this Issue 1/2021

Annals of Hematology 1/2021 Go to the issue

Correction

Correction to: Eltrombopag is effective in patients with relapse/refractory aplastic anemia—report from a single center in China

Correction

Correction to: Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia

Original Article

Characteristics of coagulation alteration in patients with COVID-19

Letter to the Editor

Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia

Original Article

Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas

Original Article

Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits